AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01293955 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JOINS 200mg
Description: 1 tablet at each time, 3 times a day
Study NCT01293955 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo of Joins 200mg
Study NCT03162536 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nemtabrutinib
Description: Nemtabrutinib will be orally administered once per day under fasted conditions (1 hour prior to or 2 hours after a meal) and is available in tablets in strengths of 5 mg or 20 mg. For Expansion Food Effect Cohort I, nemtabrutinib will be orally administered once per day under fasted and non-fasted condition.
Study NCT04092283 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboplatin
Description: Given IV
Study NCT03031730 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood sample collection
Study NCT03031730 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone Marrow Aspiration and Biopsy
Description: Undergo bone marrow aspiration and biopsy
Study NCT03031730 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carfilzomib
Description: Given IV
Study NCT03031730 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Given PO
Study NCT03031730 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone Sodium Phosphate
Description: Given IV
Study NCT03031730 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Echocardiography
Description: Undergo echocardiography
Study NCT03031730 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Given PO
Study NCT03031730 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Navtemadlin
Description: Given PO
Study NCT02384343 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine
Description: An intravenous bolus of dexmedetomidine 30 mcg (7,5 mL) administered at least five minutes after birth, in participants with shivering grade 3 or 4 on a scale described by Crossley and Mahajan.
Study NCT02384343 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline
Description: An intravenous bolus of normal saline (7,5 mL) administered at least five minutes after birth, in participants with shivering grade 3 or 4 on a scale described by Crossley and Mahajan.
Study NCT02810132 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin
Description: See above
Study NCT02810132 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: See above
Study NCT02201628 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Nasopharyngeal and oesophageal temperature probes
Study NCT02809781 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Intravenous infusion of MSCs
Description: Intravenous infusion of MSCs:Human bone marrow-derived MSCs 1.0E+6 MSC/kg, IV drop
Study NCT04092283 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Given IV
Study NCT02809781 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Etanercept
Description: 50mg,hypodermic injection,once per week, for 12 weeks
Study NCT04092283 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin
Description: Given IV
Study NCT04092283 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Given IV
Study NCT04092283 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Durvalumab
Description: Given IV
Study NCT04092283 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: Given IV
Study NCT03046550 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: placebo
Study NCT04092283 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Etoposide
Description: Given IV
Study NCT04092283 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Given IV
Study NCT04092283 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel
Description: Given IV
Study NCT01899378 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Lactobacillus reuteri DSM 17938
Description: 10\^8 CFU
Study NCT01899378 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Bifidobacterium longum infantis
Description: 10\^9 CFU
Study NCT04092283 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed Disodium
Description: Given IV
Study NCT04092283 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pemetrexed Disodium
Description: Given IV
Study NCT04417660 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: M7824
Description: Bintrafusp alfa will be administered at a dose of 1200 mg intravenously once every two weeks until disease progression or development of intolerable adverse events.
Study NCT02986737 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ACURATE neo™ and ACURATE TA™ LP
Description: ACURATE neo™ Aortic Bioprosthesis and ACURATE TA™ LP Transapical Delivery System on patients with severe aortic stenosis where conventional aortic valve replacement (AVR) via open-heart surgery is considered to be high risk
Study NCT00719173 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: aprepitant
Description: Given orally
Study NCT03840837 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rivastigmine transdermal patch
Description: Titration of transdermal rivastigmine, as per arm description.
Study NCT04005690 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cobimetinib
Description: Given PO
Study NCT04005690 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olaparib
Description: Given PO
Study NCT04005690 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Onvansertib
Description: Given PO
Study NCT04005690 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azenosertib
Description: Given PO
Study NCT04005690 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Saruparib
Description: Given PO
Study NCT04005690 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tremelimumab
Description: Given IV
Study NCT02344550 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Everolimus(afinitor)
Description: Everolimus 10mg p.o. daily
Study NCT02344550 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Letrozole
Description: Letrozole 2.5 mg p.o. daily
Study NCT02344550 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Letrozole
Description: Letrozole 2.5 mg p.o. daily
Study NCT02344550 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Leuprolide(Lorelin Depot)
Description: Leuprorelin (Lorelin Depot)3.75 mg SC in every 4 weeks
Study NCT02344550 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leuprolide(Lorelin Depot)
Description: Leuprorelin (Lorelin Depot)3.75 mg SC in every 4 weeks
Study NCT00406393 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tacrolimus
Description: Adults and Children: Tacrolimus will be given at a dose of 0.02 mg/kg every 24 hours as a continuous intravenous infusion beginning on Day -3. An effort will be made to convert the tacrolimus to oral dosing at 2-3 times the total 24-hour intravenous dose, split into 2 doses given every 12 hours as soon as clinically feasible.~The target serum level for tacrolimus is 5-10 ng/mL.
Study NCT00406393 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus
Description: Adults and Children: Tacrolimus will be given at a dose of 0.02 mg/kg every 24 hours as a continuous intravenous infusion beginning on Day -3. An effort will be made to convert the tacrolimus to oral dosing at 2-3 times the total 24-hour intravenous dose, split into 2 doses given every 12 hours as soon as clinically feasible.~The target serum level for tacrolimus is 5-10 ng/mL.
Study NCT00406393 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methotrexate
Description: Methotrexate will be given at a dose of 15 mg/m2 on Day 1 after transplantation, and at a dose of 10 mg/m2 on Days 3, 6 and 11 after transplantation.
Study NCT00406393 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sirolimus
Description: Adults: Sirolimus will be given in a loading dose of 12 mg on Day -3 followed by a daily oral dose of 4 mg per day. Doses may be repeated if the subject vomits within 15 minutes of an oral dose.~Children: Children aged \< 12.0 years OR weighing \< 40.0 kg will be given an oral loading dose of sirolimus of 3 mg/m2 followed by a daily oral dose of 1 mg/m2, rounded to the nearest full milligram.~The target serum level for sirolimus is 3-12 ng/mL.
Study NCT03390790 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine gel 2%
Description: If assigned to this intervention via randomization, participants will receive lidocaine (numbing) gel prior to their urodynamics procedure.
Study NCT03390790 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Standard lubricant gel
Description: If assigned to this intervention via randomization, participants will receive standard lubricant gel prior to their urodynamics procedure.
Study NCT03946995 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dry Needling Group
Description: Hot Pack will be applied on upper trapezius muscles before session for general relaxation for 7-10 minutes. Generalized Stretching and strengthening neck exercises will be performed. Then after wearing gloves and appropriate personal protective measures, a thin filiform needle will be inserted which will penetrate into the skin and stimulate underlying myofascial trigger points.~The treatment will be continued for 2 weeks with 2 sessions per week.
Study NCT03946995 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Graston Technique Group
Description: Hot Pack will be applied on upper trapezius muscles before session for general relaxation for 7-10 minutes. Generalized Stretching and strengthening neck exercises will be performed.~Later, lubricant will be applied to the skin, and Graston technique will be applied using instrument over the active myofascial trigger points in upper trapezius.~The treatment will be continued for 2 weeks with 2 sessions per week.
Study NCT02995135 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY987517
Description: Each 50 cm\*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm\*2 test application.~(Formulation Code: Z43-094)
Study NCT03257592 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [11C]DPA-713
Description: \[11C\]DPA-713 PET imaging
Study NCT02995135 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SFP Control
Description: Each 50 cm\*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm\*2 test application.
Study NCT02985060 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Arctic Sun
Description: 1. Induction phase: At a temperature of 4℃, a saline 500 mL or 1 L is intravenously administered.~   Arctic sun (surface freezing equipment) Target temperature: 35±0.5℃ Within 12 hours of the onset of symptoms, the therapeutic hypothermia is performed~2. Maintenance phase:The use of bedside shivering assessment scale (BSAS) The use of Columbia anti-shivering protocol,Maintenance period: 48 hours~3. Recovery phase:Rewarming velocity: 0.05\~0.1℃ (within 30 hours)
Study NCT02985060 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Standard treatment
Description: 1. All the patients receive standard treatment modalities for stroke, which are applicable to the international treatment guidelines.~2. In all the patients, neurological assessments and NIHSS scoring are performed on a daily basis for 4 days with the help of board-certified nurses or specialists in stroke.~3. Blood pressure, respiratory rate and heart rate are measured at least once at a 4-hour interval for 4 days.~4. Using an esophageal thermometer, the central temperature is measured at a 2-hour interval for 5 days.
Study NCT02985060 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Saline
Study NCT02355847 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Lectures
Description: Lectures
Study NCT00555204 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-089
Description: 10 mg - capsules once daily for 12 weeks
Study NCT04076007 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Beetroot juice
Study NCT00719173 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Description: Given IV
Study NCT00719173 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: placebo
Description: Given orally
Study NCT04063683 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anlotinib Hydrochloride, Paclitaxel, cisplatin
Description: * anlotinib: 1 capsule (10mg) once a day, d1-d14 per cycle, 3 weeks for a treatment cycle.~* Paclitaxel: intravenously infused at 135mg/ m2, administered d1 per cycle, 3 weeks for a treatment cycle.~* Cisplatin: administered after paclitaxel, intravenously infused at 60-75 mg/m2, divided into d1-d3 medications per cycle; 3 weeks for one treatment cycle.
Study NCT03684083 — intervention group
Intervention type: PROCEDURE
Intervention: bronchial biopsies
Description: bronchial fibroscopy with bronchial biopsies
Study NCT03374332 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemtuzumab Ozogamicin (GO)
Description: Patients will be given gemtuzumab ozogamicin on days 1,4, and 7. Capped at 4.5mg individual doses. Total doses capped at 13.5mg.
Study NCT03374332 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Donor Leukocytes
Description: The product will be administered unprocessed on day 8/24 hours post GO (same day as leukapheresis) with a minimum of CD3+ cells and maximum of CD3+ cells/kg irrespective of the number of CD34+ cells.
Study NCT03897010 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Socket Graft
Description: 5 patients had bilateral decayed upper premolar or anterior teeth, in one side SCPC graft was inserted in socket and in the contralateral site was a control, 5 months months postoperative core biopsies were taken from both grafted sockets and control ungrafted sockets during implant insertion. The biopsy samples from SCPC-grafted and control ungrafted sockets were fixed, decalcified and embedded into paraffin wax. All samples were serially sectioned in serial 5μm-thin sections were stained separately with Hematoxylin and Eosin staining, Sirius red and Mason trichrome and immunostaining with osteopontin.
Study NCT03897010 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Socket Graft
Description: 5 patients had bilateral decayed upper premolar or anterior teeth, in one side SCPC graft was inserted in socket and in the contralateral site was a control, 5 months months postoperative core biopsies were taken from both grafted sockets and control ungrafted sockets during implant insertion. The biopsy samples from SCPC-grafted and control ungrafted sockets were fixed, decalcified and embedded into paraffin wax. All samples were serially sectioned in serial 5μm-thin sections were stained separately with Hematoxylin and Eosin staining, Sirius red and Mason trichrome and immunostaining with osteopontin.
Study NCT04269187 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Theophylline
Description: Theophylline oral 200 mg daily for 12 days
Study NCT00641212 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Budesonide
Study NCT00641212 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT04188509 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Voxelotor
Description: All participants will receive voxelotor once daily (QD), administered orally as tablets, dispersible tablets, or a powder for oral suspension formulation (powder formulation packaged as stick packs).
Study NCT01923974 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Melatonin 10 mg
Study NCT01923974 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Melatonin 100 mg
Study NCT01923974 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT03935399 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Oxytocin
Description: 10 IU oxytocin (Pitocin) for intramuscular injection
Study NCT03935399 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Saline
Description: 1.5 ml preservative free saline for intramuscular injection
Study NCT03935399 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: 1.5 ml preservative free saline for intramuscular injection
Study NCT00350454 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: rapamycin-eluting Stent with permanent polymer
Description: due to randomization, rapamycin-eluting stent with permanent polymer will be implanted
Study NCT00350454 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: rapamycin-eluting stent with biodegradable polymer
Description: due to randomization, rapamycin-eluting stent with biodegradable polymer will be implanted
Study NCT01512251 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: BKM120 Combined with Vemurafenib (PLX4032)
Description: Phase I is 3+3 dose escalation study to identify the recommended phase 2 dose (RP2D)~Dose Level -1: BKM120 60 mg daily, Vemurafenib 480 mg bid~Dose Level 1: BKM120 60 mg daily, Vemurafenib 720 mg bid~Dose Level 2: BKM120 80 mg daiy, Vemurafenib 720 mg bid~Dose Level 3: BKM120 100 mg daiy, Vemurafenib 720 mg bid~Dose Level 4: BKM120 100 mg daiy, Vemurafenib 960 mg bid~Phase II is a single-stage, single arm prospective trial: patients will receive BKM120 and vemurafenib at the RP2D
Study NCT02084186 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: herb-partitioned moxibustion
Description: Ignited moxa cones are placed upon herbal cake. Herbs are smashed into powder. Every 2.8g medicine powder mix with 3g millet wine and then be pressed into herbal cakes which are 28mm in diameter and 7mm in high with a specific mould. Then the herbal cake with a moxa cone will be fixed on Tianshu and Shangjuxu.
Study NCT02084186 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: bran-partitioned moxibustion
Description: Ignited moxa cones are placed upon bran cake. Every 2.8g bran powder mix with 3g millet wine and then be pressed into bran cakes which are 28mm in diameter and 7mm in high with a specific mould. Then the bran cake with a moxa cone will be fixed on Tianshu and Shangjuxu.
Study NCT00350454 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: polymer-free, rapamycin-eluting stent
Description: due to randomization, polymer-free.rapamycin-eluting stent will be implanted
Study NCT01280045 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: VAGINAL HYSTERECTOMY
Description: GOSERELINE ACETATE 10.8 MG FOR THREE MONTHS; ANASTROZOL ACETATE FOR THREE MONTHS
Study NCT00555204 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-089
Description: 5 mg - capsules once daily for 12 weeks
Study NCT00555204 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-089
Description: 15 mg - capsules once daily for 12 weeks
Study NCT01280045 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: VAGINAL HYSTERECTOMY
Description: GOSERELINE ACETATE 10.8 MG FOR THREE MONTHS; ANASTROZOL ACETATE FOR THREE MONTHS
Study NCT03625271 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: The PEER Report
Description: PEER Interactive references a subject's QEEG to a normative and then symptomatic database. By comparing a given subject's QEEG to a database of QEEGs of subjects who have tried and responded to a specific medication, PEER provides useful information regarding the response of neurophysiologically similar subjects to a wide number of medications - providing clinicians with useful information as to medication outcomes before a medication regime is started. Clinicians have also reported that negative findings (in which neurophysiologically similar subjects reported resistant outcomes for certain medications) can be extremely useful in reducing trial and error. It has also been used to help select the medication that best matches the QEEG brainwave pattern.
Study NCT01784627 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: c-ASBI
Description: Participants in the c-ASBI group will complete a computerized screen for alcohol, cannabis, tobacco and other drugs, then view their screen score and 10 pages of information about the health effects of substance use and true-life stories on the computer. Their provider will see a report of their screen results and provide advice to stop or decrease their use, or, for those at high risk, referral to complete a computerized motivational enhancement therapy intervention.
Study NCT00555204 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-089
Description: 20 mg - capsules once daily for 12 weeks
Study NCT04076007 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Nitrate depleted beetroot juice
Study NCT03425422 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: VITARIA System
Description: Chronic stimulation of the right cervical vagus nerve
Study NCT01565499 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nab-paclitaxel
Study NCT03097354 — intervention group
Intervention type: OTHER
Intervention: no intervention/observational survey study design
Description: no intervention/observational survey study design
Study NCT00555204 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-089
Description: 30 mg - capsules once daily for 12 weeks